May 14, 2026 08:00AM
Mar 19, 2026 08:00AM
Feb 17, 2026 08:00AM
Dec 2, 2025 08:01AM
Dec 2, 2025 08:00AM
Nov 24, 2025 08:00AM
Nov 20, 2025 08:00AM Chemomab Therapeutics Announces Third Quarter 2025 Financial Results and Provides Corporate Update
Nov 6, 2025 08:00AM
Nov 6, 2025 08:00AM
Aug 21, 2025 08:00AM
Aug 14, 2025 08:00AM
Jun 30, 2025 08:00AM
Jun 11, 2025 08:00AM
Jun 3, 2025 08:01AM Chemomab (CMMB) Announces New Patent Awards for Its First-in-Class Agent Nebokitug that is Positioned to Potentially Become the First Approved Drug for Primary Sclerosing Cholangitis
Jun 3, 2025 08:00AM
May 15, 2025 08:00AM
May 5, 2025 08:03AM
May 5, 2025 08:00AM
Apr 28, 2025 08:03AM
Apr 28, 2025 08:00AM
Apr 21, 2025 08:00AM Chemomab Therapeutics to Present Nebokitug Clinical Data at Upcoming Scientific Conferences
Apr 15, 2025 08:00AM
Mar 27, 2025 08:30AM
Mar 27, 2025 08:30AM
Mar 6, 2025 08:00AM
Mar 3, 2025 08:00AM
Feb 19, 2025 07:00AM
Feb 19, 2025 07:00AM Chemomab Completes Successful End-of-Phase 2 Meeting and Aligns with FDA on Clear and Efficient Path to Potential Regulatory Approval for Nebokitug (CM-101) in Primary Sclerosing Cholangitis
Feb 3, 2025 07:00AM
Dec 3, 2024 07:00AM
Nov 19, 2024 07:00AM
Nov 14, 2024 07:00AM
Nov 14, 2024 07:00AM
Oct 30, 2024 07:00AM
Oct 15, 2024 07:01AM Chemomab Therapeutics (CMMB) Announces Late-Breaking Oral Presentation of CM-101 Phase 2 Results in Primary Sclerosing Cholangitis at AASLD
Oct 15, 2024 07:00AM
Oct 1, 2024 07:00AM
Aug 21, 2024 07:00AM
Jul 25, 2024 07:01AM
Jul 25, 2024 07:00AM
Jun 18, 2024 07:03AM
Jun 18, 2024 07:00AM Chemomab Therapeutics Announces New Publications Reinforcing the Clinical Potential of Its CCL24-Neutralizing Antibody CM-101 in Primary Sclerosing Cholangitis
May 9, 2024 07:00AM
Apr 2, 2024 07:00AM
Mar 25, 2024 07:07AM
Mar 25, 2024 07:06AM
Mar 7, 2024 07:00AM
Feb 20, 2024 07:10AM
Feb 20, 2024 07:00AM Chemomab Awarded New Patents for CM-101, Its First-in Class Monoclonal Antibody in Clinical Development for Fibro-Inflammatory Diseases
Jan 30, 2024 07:04AM

323,736 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All